Characterising treatment outcomes of patients achieving quarterly aflibercept dosing for neovascular age-related macular degeneration: real-world clinical outcomes from a large tertiary care centre
Background and objective To evaluate the proportion of patients achieving a 12-week (q12) aflibercept dosing interval in patients with neovascular age-related macular degeneration (nAMD). Patients and methods Retrospective, comparative, non-randomised electronic medical record (EMR) database study o...
Gespeichert in:
| Veröffentlicht in: | Eye (London) 2023-03, Vol.37 (4), p.779-784 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 784 |
|---|---|
| container_issue | 4 |
| container_start_page | 779 |
| container_title | Eye (London) |
| container_volume | 37 |
| creator | Fu, Dun Jack Hanumunthadu, Daren Keenan, Tiarnan D. L. Wagner, Siegfried Balsakas, Konstantinos Keane, Pearse A. Patel, Praveen J. |
| description | Background and objective
To evaluate the proportion of patients achieving a 12-week (q12) aflibercept dosing interval in patients with neovascular age-related macular degeneration (nAMD).
Patients and methods
Retrospective, comparative, non-randomised electronic medical record (EMR) database study of the Moorfields database of treatment-naïve nAMD eyes. Extraction criteria included at least 7 aflibercept injections in first year of treatment, AMD in the diagnosis field of EMR, and minimum of 1 year follow-up data.
Results
There were 2416 eyes of 2163 patients started on anti-vascular endothelial growth factor (anti-VEGF) between 01-11-2013 & 14-02-2020 who had received at least 7 aflibercept intravitreal injections (electronic database accessed March 2021). Of these, 1674 (68%) eyes of 1537 patients had at least one q12 dosing interval (>=84 and |
| doi_str_mv | 10.1038/s41433-022-02220-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9998641</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2712845537</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-b5caa057a282ed7c6ecc76f14b6f0cd83ee0651517b0de1cdfe8b1695652f76f3</originalsourceid><addsrcrecordid>eNp9ks1u1DAUhS0EokPhBVggS2zYBOwkzg8LpGrEn1SJDUjsrBvnJuPKiae2M6gPyHtxZ1JaYMHCtuT73XOPrcPYcyleS1E0b2Ipy6LIRJ4fVy4y-YBtZFlXmSpV-ZBtRKtERpXvZ-xJjFdCULEWj9lZUYlG0bZhP7c7CGASBhvtPPIUENKEc-J-ScZPGLkf-B6SpbvIwewsHo7g9QKButwNh8HZDoPBfeK9P6kMPvAZ_QGiWRwEDiNmAR0k7PkE612PI84YSNnPbzmNddkPH1zPjbOzNeDuHQzBTxw4dY3IaWiyEG64gYDckK2AT9mjAVzEZ7fnOfv24f3X7afs8svHz9uLy8yUdZmyThkAoWrImxz72lRoTF0NsuyqQZi-KRBFpaSSdSd6lKYfsOlk1apK5QOBxTl7t-rul27C_jQcnN4HO5Ej7cHqvyuz3enRH3Tbtk1VShJ4dSsQ_PWCMenJRoPOAX3XEnVey7wplSpqQl_-g175Jcz0PKIaRQGQMicqXykTfIwBhzszUuhjSvSaEk0J0aeU6KOLF38-467ldywIKFYgUmkeMdzP_o_sLyecz8Y</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2785038112</pqid></control><display><type>article</type><title>Characterising treatment outcomes of patients achieving quarterly aflibercept dosing for neovascular age-related macular degeneration: real-world clinical outcomes from a large tertiary care centre</title><source>MEDLINE</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Fu, Dun Jack ; Hanumunthadu, Daren ; Keenan, Tiarnan D. L. ; Wagner, Siegfried ; Balsakas, Konstantinos ; Keane, Pearse A. ; Patel, Praveen J.</creator><creatorcontrib>Fu, Dun Jack ; Hanumunthadu, Daren ; Keenan, Tiarnan D. L. ; Wagner, Siegfried ; Balsakas, Konstantinos ; Keane, Pearse A. ; Patel, Praveen J.</creatorcontrib><description>Background and objective
To evaluate the proportion of patients achieving a 12-week (q12) aflibercept dosing interval in patients with neovascular age-related macular degeneration (nAMD).
Patients and methods
Retrospective, comparative, non-randomised electronic medical record (EMR) database study of the Moorfields database of treatment-naïve nAMD eyes. Extraction criteria included at least 7 aflibercept injections in first year of treatment, AMD in the diagnosis field of EMR, and minimum of 1 year follow-up data.
Results
There were 2416 eyes of 2163 patients started on anti-vascular endothelial growth factor (anti-VEGF) between 01-11-2013 & 14-02-2020 who had received at least 7 aflibercept intravitreal injections (electronic database accessed March 2021). Of these, 1674 (68%) eyes of 1537 patients had at least one q12 dosing interval (>=84 and < =98 days between injections) during the first 2 years of treatment. This included 926 (61.8%) female patients and 856 (right eyes age at 1st injection), 936 (62.4%) Caucasian, and 32 (2.1%) Afro-Caribbean patients. The median time to the first q12 injection (95% confidence interval) was 1.76 years (1.70–1.86) with mean (±SD) of 11.8 (±6.0) injections. Visual acuity (ETDRS letters) of the eyes without q12 injection and eyes with a q12 injection was 57.9 ± 14.7 and 56.7 ± 14.8 respectively at baseline, 61.4 ± 18.1 and 63.0 ± 15.9 respectively at 12 months and 61.2 ± 20.1 and 61.1 ± 17.8 respectively at 24 months.
Conclusion
68% of eyes were able to achieve a q12 injection dose within the first 2 years of treatment. Eyes achieving a q12 injection in the first 2 years achieved a similar visual acuity outcome at both 1 and 2-year follow-up to those unable to do so, with a fewer number of total injections.</description><identifier>ISSN: 0950-222X</identifier><identifier>EISSN: 1476-5454</identifier><identifier>DOI: 10.1038/s41433-022-02220-1</identifier><identifier>PMID: 36085360</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/53/2423 ; 692/699/3161/1626 ; Acuity ; Age ; Angiogenesis Inhibitors - therapeutic use ; Dosage ; Electronic medical records ; Eye ; Female ; Humans ; Infant ; Injection ; Intravitreal Injections ; Laboratory Medicine ; Macular degeneration ; Macular Degeneration - drug therapy ; Male ; Medicine ; Medicine & Public Health ; Ophthalmology ; Patients ; Pharmaceutical Sciences/Technology ; Receptors, Vascular Endothelial Growth Factor ; Recombinant Fusion Proteins - therapeutic use ; Retrospective Studies ; Surgery ; Surgical Oncology ; Tertiary Care Centers ; Treatment Outcome ; Vascular endothelial growth factor ; Visual acuity ; Wet Macular Degeneration - diagnosis ; Wet Macular Degeneration - drug therapy</subject><ispartof>Eye (London), 2023-03, Vol.37 (4), p.779-784</ispartof><rights>The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2022. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.</rights><rights>The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-b5caa057a282ed7c6ecc76f14b6f0cd83ee0651517b0de1cdfe8b1695652f76f3</citedby><cites>FETCH-LOGICAL-c474t-b5caa057a282ed7c6ecc76f14b6f0cd83ee0651517b0de1cdfe8b1695652f76f3</cites><orcidid>0000-0002-9239-745X ; 0000-0002-2253-1772 ; 0000-0001-8682-4067 ; 0000-0003-2852-6912</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998641/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998641/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36085360$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fu, Dun Jack</creatorcontrib><creatorcontrib>Hanumunthadu, Daren</creatorcontrib><creatorcontrib>Keenan, Tiarnan D. L.</creatorcontrib><creatorcontrib>Wagner, Siegfried</creatorcontrib><creatorcontrib>Balsakas, Konstantinos</creatorcontrib><creatorcontrib>Keane, Pearse A.</creatorcontrib><creatorcontrib>Patel, Praveen J.</creatorcontrib><title>Characterising treatment outcomes of patients achieving quarterly aflibercept dosing for neovascular age-related macular degeneration: real-world clinical outcomes from a large tertiary care centre</title><title>Eye (London)</title><addtitle>Eye</addtitle><addtitle>Eye (Lond)</addtitle><description>Background and objective
To evaluate the proportion of patients achieving a 12-week (q12) aflibercept dosing interval in patients with neovascular age-related macular degeneration (nAMD).
Patients and methods
Retrospective, comparative, non-randomised electronic medical record (EMR) database study of the Moorfields database of treatment-naïve nAMD eyes. Extraction criteria included at least 7 aflibercept injections in first year of treatment, AMD in the diagnosis field of EMR, and minimum of 1 year follow-up data.
Results
There were 2416 eyes of 2163 patients started on anti-vascular endothelial growth factor (anti-VEGF) between 01-11-2013 & 14-02-2020 who had received at least 7 aflibercept intravitreal injections (electronic database accessed March 2021). Of these, 1674 (68%) eyes of 1537 patients had at least one q12 dosing interval (>=84 and < =98 days between injections) during the first 2 years of treatment. This included 926 (61.8%) female patients and 856 (right eyes age at 1st injection), 936 (62.4%) Caucasian, and 32 (2.1%) Afro-Caribbean patients. The median time to the first q12 injection (95% confidence interval) was 1.76 years (1.70–1.86) with mean (±SD) of 11.8 (±6.0) injections. Visual acuity (ETDRS letters) of the eyes without q12 injection and eyes with a q12 injection was 57.9 ± 14.7 and 56.7 ± 14.8 respectively at baseline, 61.4 ± 18.1 and 63.0 ± 15.9 respectively at 12 months and 61.2 ± 20.1 and 61.1 ± 17.8 respectively at 24 months.
Conclusion
68% of eyes were able to achieve a q12 injection dose within the first 2 years of treatment. Eyes achieving a q12 injection in the first 2 years achieved a similar visual acuity outcome at both 1 and 2-year follow-up to those unable to do so, with a fewer number of total injections.</description><subject>692/53/2423</subject><subject>692/699/3161/1626</subject><subject>Acuity</subject><subject>Age</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Dosage</subject><subject>Electronic medical records</subject><subject>Eye</subject><subject>Female</subject><subject>Humans</subject><subject>Infant</subject><subject>Injection</subject><subject>Intravitreal Injections</subject><subject>Laboratory Medicine</subject><subject>Macular degeneration</subject><subject>Macular Degeneration - drug therapy</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Ophthalmology</subject><subject>Patients</subject><subject>Pharmaceutical Sciences/Technology</subject><subject>Receptors, Vascular Endothelial Growth Factor</subject><subject>Recombinant Fusion Proteins - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Tertiary Care Centers</subject><subject>Treatment Outcome</subject><subject>Vascular endothelial growth factor</subject><subject>Visual acuity</subject><subject>Wet Macular Degeneration - diagnosis</subject><subject>Wet Macular Degeneration - drug therapy</subject><issn>0950-222X</issn><issn>1476-5454</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9ks1u1DAUhS0EokPhBVggS2zYBOwkzg8LpGrEn1SJDUjsrBvnJuPKiae2M6gPyHtxZ1JaYMHCtuT73XOPrcPYcyleS1E0b2Ipy6LIRJ4fVy4y-YBtZFlXmSpV-ZBtRKtERpXvZ-xJjFdCULEWj9lZUYlG0bZhP7c7CGASBhvtPPIUENKEc-J-ScZPGLkf-B6SpbvIwewsHo7g9QKButwNh8HZDoPBfeK9P6kMPvAZ_QGiWRwEDiNmAR0k7PkE612PI84YSNnPbzmNddkPH1zPjbOzNeDuHQzBTxw4dY3IaWiyEG64gYDckK2AT9mjAVzEZ7fnOfv24f3X7afs8svHz9uLy8yUdZmyThkAoWrImxz72lRoTF0NsuyqQZi-KRBFpaSSdSd6lKYfsOlk1apK5QOBxTl7t-rul27C_jQcnN4HO5Ej7cHqvyuz3enRH3Tbtk1VShJ4dSsQ_PWCMenJRoPOAX3XEnVey7wplSpqQl_-g175Jcz0PKIaRQGQMicqXykTfIwBhzszUuhjSvSaEk0J0aeU6KOLF38-467ldywIKFYgUmkeMdzP_o_sLyecz8Y</recordid><startdate>20230301</startdate><enddate>20230301</enddate><creator>Fu, Dun Jack</creator><creator>Hanumunthadu, Daren</creator><creator>Keenan, Tiarnan D. L.</creator><creator>Wagner, Siegfried</creator><creator>Balsakas, Konstantinos</creator><creator>Keane, Pearse A.</creator><creator>Patel, Praveen J.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9239-745X</orcidid><orcidid>https://orcid.org/0000-0002-2253-1772</orcidid><orcidid>https://orcid.org/0000-0001-8682-4067</orcidid><orcidid>https://orcid.org/0000-0003-2852-6912</orcidid></search><sort><creationdate>20230301</creationdate><title>Characterising treatment outcomes of patients achieving quarterly aflibercept dosing for neovascular age-related macular degeneration: real-world clinical outcomes from a large tertiary care centre</title><author>Fu, Dun Jack ; Hanumunthadu, Daren ; Keenan, Tiarnan D. L. ; Wagner, Siegfried ; Balsakas, Konstantinos ; Keane, Pearse A. ; Patel, Praveen J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-b5caa057a282ed7c6ecc76f14b6f0cd83ee0651517b0de1cdfe8b1695652f76f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>692/53/2423</topic><topic>692/699/3161/1626</topic><topic>Acuity</topic><topic>Age</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Dosage</topic><topic>Electronic medical records</topic><topic>Eye</topic><topic>Female</topic><topic>Humans</topic><topic>Infant</topic><topic>Injection</topic><topic>Intravitreal Injections</topic><topic>Laboratory Medicine</topic><topic>Macular degeneration</topic><topic>Macular Degeneration - drug therapy</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Ophthalmology</topic><topic>Patients</topic><topic>Pharmaceutical Sciences/Technology</topic><topic>Receptors, Vascular Endothelial Growth Factor</topic><topic>Recombinant Fusion Proteins - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Tertiary Care Centers</topic><topic>Treatment Outcome</topic><topic>Vascular endothelial growth factor</topic><topic>Visual acuity</topic><topic>Wet Macular Degeneration - diagnosis</topic><topic>Wet Macular Degeneration - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fu, Dun Jack</creatorcontrib><creatorcontrib>Hanumunthadu, Daren</creatorcontrib><creatorcontrib>Keenan, Tiarnan D. L.</creatorcontrib><creatorcontrib>Wagner, Siegfried</creatorcontrib><creatorcontrib>Balsakas, Konstantinos</creatorcontrib><creatorcontrib>Keane, Pearse A.</creatorcontrib><creatorcontrib>Patel, Praveen J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Eye (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fu, Dun Jack</au><au>Hanumunthadu, Daren</au><au>Keenan, Tiarnan D. L.</au><au>Wagner, Siegfried</au><au>Balsakas, Konstantinos</au><au>Keane, Pearse A.</au><au>Patel, Praveen J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characterising treatment outcomes of patients achieving quarterly aflibercept dosing for neovascular age-related macular degeneration: real-world clinical outcomes from a large tertiary care centre</atitle><jtitle>Eye (London)</jtitle><stitle>Eye</stitle><addtitle>Eye (Lond)</addtitle><date>2023-03-01</date><risdate>2023</risdate><volume>37</volume><issue>4</issue><spage>779</spage><epage>784</epage><pages>779-784</pages><issn>0950-222X</issn><eissn>1476-5454</eissn><abstract>Background and objective
To evaluate the proportion of patients achieving a 12-week (q12) aflibercept dosing interval in patients with neovascular age-related macular degeneration (nAMD).
Patients and methods
Retrospective, comparative, non-randomised electronic medical record (EMR) database study of the Moorfields database of treatment-naïve nAMD eyes. Extraction criteria included at least 7 aflibercept injections in first year of treatment, AMD in the diagnosis field of EMR, and minimum of 1 year follow-up data.
Results
There were 2416 eyes of 2163 patients started on anti-vascular endothelial growth factor (anti-VEGF) between 01-11-2013 & 14-02-2020 who had received at least 7 aflibercept intravitreal injections (electronic database accessed March 2021). Of these, 1674 (68%) eyes of 1537 patients had at least one q12 dosing interval (>=84 and < =98 days between injections) during the first 2 years of treatment. This included 926 (61.8%) female patients and 856 (right eyes age at 1st injection), 936 (62.4%) Caucasian, and 32 (2.1%) Afro-Caribbean patients. The median time to the first q12 injection (95% confidence interval) was 1.76 years (1.70–1.86) with mean (±SD) of 11.8 (±6.0) injections. Visual acuity (ETDRS letters) of the eyes without q12 injection and eyes with a q12 injection was 57.9 ± 14.7 and 56.7 ± 14.8 respectively at baseline, 61.4 ± 18.1 and 63.0 ± 15.9 respectively at 12 months and 61.2 ± 20.1 and 61.1 ± 17.8 respectively at 24 months.
Conclusion
68% of eyes were able to achieve a q12 injection dose within the first 2 years of treatment. Eyes achieving a q12 injection in the first 2 years achieved a similar visual acuity outcome at both 1 and 2-year follow-up to those unable to do so, with a fewer number of total injections.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>36085360</pmid><doi>10.1038/s41433-022-02220-1</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-9239-745X</orcidid><orcidid>https://orcid.org/0000-0002-2253-1772</orcidid><orcidid>https://orcid.org/0000-0001-8682-4067</orcidid><orcidid>https://orcid.org/0000-0003-2852-6912</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0950-222X |
| ispartof | Eye (London), 2023-03, Vol.37 (4), p.779-784 |
| issn | 0950-222X 1476-5454 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9998641 |
| source | MEDLINE; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | 692/53/2423 692/699/3161/1626 Acuity Age Angiogenesis Inhibitors - therapeutic use Dosage Electronic medical records Eye Female Humans Infant Injection Intravitreal Injections Laboratory Medicine Macular degeneration Macular Degeneration - drug therapy Male Medicine Medicine & Public Health Ophthalmology Patients Pharmaceutical Sciences/Technology Receptors, Vascular Endothelial Growth Factor Recombinant Fusion Proteins - therapeutic use Retrospective Studies Surgery Surgical Oncology Tertiary Care Centers Treatment Outcome Vascular endothelial growth factor Visual acuity Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy |
| title | Characterising treatment outcomes of patients achieving quarterly aflibercept dosing for neovascular age-related macular degeneration: real-world clinical outcomes from a large tertiary care centre |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T23%3A14%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characterising%20treatment%20outcomes%20of%20patients%20achieving%20quarterly%20aflibercept%20dosing%20for%20neovascular%20age-related%20macular%20degeneration:%20real-world%20clinical%20outcomes%20from%20a%20large%20tertiary%20care%20centre&rft.jtitle=Eye%20(London)&rft.au=Fu,%20Dun%20Jack&rft.date=2023-03-01&rft.volume=37&rft.issue=4&rft.spage=779&rft.epage=784&rft.pages=779-784&rft.issn=0950-222X&rft.eissn=1476-5454&rft_id=info:doi/10.1038/s41433-022-02220-1&rft_dat=%3Cproquest_pubme%3E2712845537%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2785038112&rft_id=info:pmid/36085360&rfr_iscdi=true |